Argent Advisors Inc. increased its position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 68.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,877 shares of the pharmaceutical company's stock after buying an additional 22,220 shares during the quarter. Argent Advisors Inc.'s holdings in GSK were worth $2,126,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the company. Verity Asset Management Inc. lifted its holdings in shares of GSK by 3.2% in the first quarter. Verity Asset Management Inc. now owns 16,944 shares of the pharmaceutical company's stock valued at $656,000 after buying an additional 524 shares during the period. Hills Bank & Trust Co raised its position in shares of GSK by 4.6% during the first quarter. Hills Bank & Trust Co now owns 27,918 shares of the pharmaceutical company's stock worth $1,082,000 after purchasing an additional 1,234 shares during the period. Colonial River Investments LLC acquired a new stake in shares of GSK during the first quarter worth $211,000. Allspring Global Investments Holdings LLC raised its position in shares of GSK by 11.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 12,413 shares of the pharmaceutical company's stock worth $464,000 after purchasing an additional 1,248 shares during the period. Finally, Money Concepts Capital Corp raised its position in shares of GSK by 3.0% during the first quarter. Money Concepts Capital Corp now owns 14,479 shares of the pharmaceutical company's stock worth $561,000 after purchasing an additional 425 shares during the period. Institutional investors and hedge funds own 15.74% of the company's stock.
GSK Stock Down 0.0%
NYSE:GSK opened at $38.55 on Monday. The firm has a market capitalization of $78.92 billion, a price-to-earnings ratio of 19.87, a PEG ratio of 1.35 and a beta of 0.52. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $44.67. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.21. The business's fifty day moving average price is $38.86 and its 200 day moving average price is $36.97.
GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The company had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same period in the prior year, the firm posted $0.43 EPS. The business's revenue was up 2.1% compared to the same quarter last year. On average, sell-side analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.
GSK Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be given a $0.4216 dividend. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.38%. The ex-dividend date is Friday, May 16th. GSK's dividend payout ratio is presently 87.11%.
Analysts Set New Price Targets
GSK has been the topic of a number of recent analyst reports. Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. BNP Paribas initiated coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price on the stock. Finally, Wall Street Zen lowered GSK from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $37.38.
Get Our Latest Analysis on GSK
About GSK
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Further Reading
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
